📢 Results from NMDP's ACCESS trial are published in Journal of Clinical Oncology ! The data show PTCy—a treatment to prevent GVHD—makes MMUD transplants comparable to matched donor outcomes. 📈 This is a major step toward expanding access to life-saving transplant. ➡️ go.nmdp.org/3SRTmgf

1/ 📢 Just published in JCO: the ACCESS trial. A prospective study of MMUD PB HCT + PTCy. Solid outcomes. Low GVHD. Expanded access. For patients with limited donor options, this changes the conversation. #HCT #GVHD #TransplantEquity #HealthcareAccess

“In terms of HLA matching, I don’t see why haploidentical family donors should be any better than haploidentical unrelated donors” Thanks to Syed Ali Abutalib for the opportunity to discuss HLA mismatching in current HCT with Ephraim Fuchs ascopost.com/issues/june-25… via @ascopost

Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR Transplantation and Cellular Therapy Journal astctjournal.org/article/S2666-…

No dia 22 de agosto, #SBTMO2025 apresenta: Histocompatibilidade - Sessão Conjunta SBTMO & ABHI Confira a programação completa em nosso site e inscreva-se: congressosbtmo.org.br *Apoio institucional: ABHonline-HLA #Histocompatibilidade #SBTMO #TMO #ABHI #TMOJuntos

🚨 Transplant teams—need to quickly & clearly reference the 2025 Donor Selection Guidelines? This new summary highlights: • Early use of search prognosis • Donor selection recommendations • DSA considerations with MMUD 🔗 go.nmdp.org/DSG 📩 [email protected]

👉🏼🔔Donor Type in Allo-HCT for Myelofibrosis including largest number of MMRD reported to date The EBMT #MPNsm The EBMT Trainee Committee - 2809 MF patients - 3-year OS rates 65.8%, 61.5%, 53.2%, and 57.7% for MSD, MUD, MMUD, and MMRD respectively - interesting data with PTCY in MMUD

❓ Does HLA matter in HSCT with PTCy? Join Prof. Katharina Fleischhauer & Dr. Leslie Kean at COSTEM 2025 for this exciting debate in Stem Cell Transplantation & Cellular Therapies. 📅 Sept 25–28 | Berlin 📌 Register today: bit.ly/4a1Pzn7 Nico Gagelmann

Out now in Haematologica 🎉 Not all HLA mismatches carry the same immunological risk, even in the PTCy era! Read our comment on the Sanz et al manuscript in this month's Haematologica 🙌🏽 haematologica.org/newsletter/v1/…

This study highlights the importance of donor age in allogeneic stem cell transplant with PTCy. Younger donors under 30 were linked to better GRFS, lower GVHD and reduced treatment-related mortality. Read the full article: astctjournal.org/article/S2666-…

Misuse of p-values is a prevalent issue in scientific research. P-values are often misunderstood and misapplied, leading to incorrect conclusions. A p-value measures the probability of obtaining results at least as extreme as the observed ones, assuming that the null hypothesis

When a matched donor isn’t available, moving quickly to an alternative donor achieves similar outcome, thanks to advances like post-transplant cyclophosphamide, showing that time to transplant can matter as much as HLA matching. Out in Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Donor choice by ⁦Mohamad Mohty⁩ at #IACH 2025

We are extremely happy to be coordinating 1 of these workshops with Annalisa Ruggeri , focusing on the role of HLA in HCT. Earlier last week, we had our in-person meeting in Berlin, in which colleagues from 🇮🇹🇩🇪🇬🇧🇪🇸🇫🇷🇺🇸🇧🇷🇦🇺 met to discuss the draft expert recommendations.

Avoid misconceptions about CIs A frequentist confidence interval is an interval that we calculate from data in order to make a guess at where the true value of something (like an average or effect) might be, but it isn't a statement of the probability about the true value